Peoples Financial Services CORP. Purchases 727 Shares of Novo Nordisk A/S (NYSE:NVO)

Peoples Financial Services CORP. lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 9.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,449 shares of the company’s stock after purchasing an additional 727 shares during the period. Peoples Financial Services CORP.’s holdings in Novo Nordisk A/S were worth $727,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Pines Wealth Management LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $331,000. GuoLine Advisory Pte Ltd grew its holdings in shares of Novo Nordisk A/S by 20.5% in the fourth quarter. GuoLine Advisory Pte Ltd now owns 346,500 shares of the company’s stock worth $29,806,000 after purchasing an additional 58,900 shares during the last quarter. Wallace Advisory Group LLC grew its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Wallace Advisory Group LLC now owns 11,641 shares of the company’s stock worth $1,001,000 after purchasing an additional 930 shares during the last quarter. Signal Advisors Wealth LLC grew its holdings in shares of Novo Nordisk A/S by 39.1% in the fourth quarter. Signal Advisors Wealth LLC now owns 15,874 shares of the company’s stock worth $1,365,000 after purchasing an additional 4,464 shares during the last quarter. Finally, AAFMAA Wealth Management & Trust LLC grew its holdings in shares of Novo Nordisk A/S by 35.2% in the fourth quarter. AAFMAA Wealth Management & Trust LLC now owns 17,357 shares of the company’s stock worth $1,493,000 after purchasing an additional 4,519 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $81.27 on Wednesday. Novo Nordisk A/S has a twelve month low of $80.05 and a twelve month high of $148.15. The company’s 50 day moving average is $99.26 and its 200 day moving average is $118.18. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market cap of $364.70 billion, a PE ratio of 26.30, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on NVO shares. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.